Disease · MONDO_0005184
Comparisons in its trials52
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 52
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): Number of Patients With Adverse Events | 560 of 561 | 543 of 547 | 1,108 | NCT02993731 | Trial comparisons |
| Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): deaths from any cause | 419 of 561 | 400 of 547 | 1,108 | NCT02993731 | Trial comparisons |
| Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): serious adverse events | 330 of 561 | 273 of 547 | 1,108 | NCT02993731 | Trial comparisons |
| PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) | 8 of 325 | 4 of 156 | 481 | NCT02715804 | Trial comparisons |
| PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: Number of Participants With Treatment-Emergent Adverse Events (AEs) | 325 of 325 | 156 of 156 | 481 | NCT02715804 | Trial comparisons |
| PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: deaths from any cause | 222 of 325 | 106 of 156 | 481 | NCT02715804 | Trial comparisons |
| PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: serious adverse events | 187 of 325 | 80 of 156 | 481 | NCT02715804 | Trial comparisons |
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine vs AG: Nab-paclitaxel + Gemcitabine: deaths from any cause | 131 of 166 | 87 of 113 | 279 | NCT01839487 | Trial comparisons |
| PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine vs AG: Nab-paclitaxel + Gemcitabine: serious adverse events | 101 of 160 | 58 of 100 | 260 | NCT01839487 | Trial comparisons |
| GEMPAX vs Control: deaths from any cause | 131 of 140 | 68 of 71 | 211 | NCT03943667 | Trial comparisons |
| GEMPAX vs Control: serious adverse events | 71 of 140 | 26 of 71 | 211 | NCT03943667 | Trial comparisons |
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) vs Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx): Incidence of Adverse Events Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4 and the Patient-Reported Outcomes Version of the CTCAE | 66 of 66 | 55 of 55 | 121 | NCT02839343 | Trial comparisons |
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) vs Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx): deaths from any cause | 42 of 66 | 26 of 55 | 121 | NCT02839343 | Trial comparisons |
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) vs Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx): serious adverse events | 33 of 66 | 28 of 55 | 121 | NCT02839343 | Trial comparisons |
mFOLFIRINOX ->Surg ->mFOLFIRINOX vs Gem/Nab-P ->Surg ->Gem/Nab-P: Number of Participants With a Response Following Preoperative Chemotherapy, Including Confirmed and Unconfirmed, Complete and Partial Response, Per RECIST 1.1. | 5 of 55 | 10 of 47 | 102 | NCT02562716 | Trial comparisons |
| mFOLFIRINOX ->Surg ->mFOLFIRINOX vs Gem/Nab-P ->Surg ->Gem/Nab-P: Number of Patients Going to Surgery for Resection After Preoperative Chemotherapy. | 40 of 55 | 33 of 47 | 102 | NCT02562716 | Trial comparisons |
| mFOLFIRINOX->Surg->mFOLFIRINOX vs Gem/Nab-P->Surg->Gem/Nab-P: deaths from any cause | 32 of 55 | 32 of 47 | 102 | NCT02562716 | Trial comparisons |
| mFOLFIRINOX->Surg->mFOLFIRINOX vs Gem/Nab-P->Surg->Gem/Nab-P: serious adverse events | 3 of 53 | 5 of 45 | 98 | NCT02562716 | Trial comparisons |
| All Eligible - FOLFIRINOX + Radiation vs Resected Participants - FOLFIRINOX + Radiation: Rate of R0 Resection | 31 of 48 | 31 of 32 | 80 | NCT01591733 | Trial comparisons |
| Arm 1 - Acalabrutinib Monotherapy vs Arm 2- Acalabrutinib+Pembrolizumab: deaths from any cause | 30 of 35 | 34 of 38 | 73 | NCT02362048 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005184/comparisons